ClinicalTrials.gg
RecruitingNCT06421831Updated Nov 17, 2026

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

A Phase 1/2 interventional study of GC101 in Spinal Muscular Atrophy Type 3, sponsored by GeneCradle Inc. Recruiting at 1 site in China. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by GeneCradle Inc · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Nov 17, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Study summary

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.

Read the detailed description

The purpose of this trial is to evaluate safety and efficacy of gene therapy drug GC101 in SMA 3 patients. Open-label, dose-escalation clinical trials of GC101 will be conducted in multiple centers in China.

GC101 will be administrated intrathecally. Short-term safety will be evaluated in 52 weeks and enter long-term follow-up study of 5 years at will. Patients will be tested at baseline and followed up at various time points.

The primary analysis for efficacy will be assessed at 12 months after treatment with GC101 on the changes from baseline HFMSE (Hammersmith Functional Motor Scale Expanded) and RULM(Revised Upper Limb Module) scores for patients of age ≥ 6 years old.

02

Conditions studied

  • Spinal Muscular Atrophy Type 3

Keywords

  • SMA type 3
03

In context

Spinal Muscular Atrophies of Childhood

61 studies on the registry are indexed under Spinal Muscular Atrophies of Childhood; 18 are open to participants now.

This study's planned enrollment of 21 is above the median of 15 across 41 interventional studies indexed under Spinal Muscular Atrophies of Childhood.

Browse Spinal Muscular Atrophies of Childhood studies →

Lead sponsor

GeneCradle Inc is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥2 years of age on the day of signing the form;
  • Genetic and clinical diagnosis of type 3 SMA with bi-allelic deletion of SMN1 of 5qSMA;
  • Hammersmith Functional Motor Scale - Expanded (HFMSE) score is between 10 and 54 at screening;
  • Female patients of childbearing age who are pregnant or lactating, as well as all enrolled patients (both male and female), should take effective measures within 6 months after the treatment;
  • Patients or patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.

Exclusion criteria

Exclusion Criteria:

  • Patient who has participated in any previous gene therapy research trials;
  • Patient who has AAV9 neutralizing antibody titer ≥1:200;
  • Patient who has received Nusinersen within 120 days and Risdiplam within 15 days before treatment;
  • Patient who requires invasive or non-invasive ventilatory support averaging≥16 hours/day at screening;
  • SMN2 copy numbers >4;
  • Patient who needs nasal or gastric tube feeding for eating;
  • Patient who is positive for (HIV) antibody, surface antigen, antibody, or treponema pallidum antibody;
  • Known allergy or to prednisolone or other glucocorticosteroids or their
  • Severe contractures at screening that interfere with either the ability to attain/demonstrate functional measures or with the ability to receive intrathecal (IT) dosing;
  • Patient who has other serious diseases, such as severe cardiovascular and cerebrovascular diseases, digestive system diseases, urinary system diseases, endocrine system diseases, hematological diseases, immune system diseases, nervous system diseases (including but not limited to epilepsy, meningitis, history of convulsions or seizures, cerebrospinal fluid circulation disorders), and mental illnesses, etc.;
  • Patient with previous injuries (such as upper or lower limb fractures) or surgical operations that have not fully recovered or reached a stable state;
  • Vaccination no longer than 2 weeks before treatment;
  • Patient who has any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    single dose cohort

    1.2x10\^14 vg/person of GC101 delivered one-time intrathecally

    Genetic: GC101

Interventions

  • GeneticGC101

    Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Frequency of treatment-related adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests

    Time frame: 52 weeks

  2. Change from baseline on Hammersmith Functional Motor Scale - Expanded (HFMSE) scores at Month 12

    HFMSE consists of 33 activities that can be scored one of three ways: 0 for unable to perform, 1 for performs with modification/adaptation, and 2 for performs without modification.

    Time frame: 52 weeks

Secondary outcomes

  1. The proportion of patients whose HFMSE improvement ≥ 3 points at Month 12

    HFMSE ≥3 points:minimal clinically important differences (MCID) were considered for the outcomes:

    Time frame: 52 weeks

  2. Change from baseline on Revised Upper Limb Module (RULM) scores at Month 12

    RULM is a 20-item evaluation of upper limb function primarily used for those with SMA who are non-ambulatory (young children through adults).

    Time frame: 52 weeks

Other outcomes

  1. The proportion of patients whose Clinical Global Impression (CGI) is improved at Month 12

    The Clinical Global Impressions (CGI) is a widely used assessment tool in clinical practice, particularly for evaluating the severity of a patient's illness and the effectiveness of treatments. The CGI consists of two primary components: CGI-Severity (CGI-S): This scale measures how ill a patient is at a given time, with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). It reflects the clinician's overall view of the patient's mental health status based on all available information, including symptoms, behavior, and functional impairments experienced in the past week. CGI-Improvement (CGI-I): This scale rates the change in the patient's condition compared to a baseline state, prior to the initiation of treatment. It uses a seven-point scale where 1 indicates "very much improved" and 7 indicates "very much worse." The CGI-I captures the overall change in the patient's clinical state since the start of treatment.

    Time frame: 52 weeks

  2. The proportion of patients whose Motor Function Measure (MFM) is improved or maintained at Month 12

    The Motor Function Measure (MFM) is a validated scale specifically designed to assess motor function in individuals with neuromuscular disorders like Spinal Muscular Atrophy (SMA). It consists of 32 items that are scored on a 4-point Likert scale, reflecting a person's maximum ability to perform tasks without assistance.

    Time frame: 52 weeks

  3. Change from baseline of Forced Vital Capacity (FVC) at Month 12 ( for patients > 6 years)

    Time frame: 52 weeks

  4. Change from baseline of Forced Expiratory Volume in 1 Second (FEV1) at Month 12 ( for patients > 6 years)

    Time frame: 52 weeks

  5. Change from baseline of Maximal Inspiratory Pressure (MIP) at Month 12 ( for patients > 6 years)

    Time frame: 52 weeks

  6. Change from baseline of Maximal Expiratory Pressure (MEP) at Month 12 ( for patients > 6 years)

    Time frame: 52 weeks

  7. Change from baseline of 6 minutes walk test (6MWT) at Month 12 (for ambulatory patients)

    The 6MWT is used for ambulatory participants with SMA and measures the total distance walked in 6 minutes.

    Time frame: 52 weeks

  8. Change from baseline of SMA Independence Scale (SMAIS) at Month 12

    The SMA Independence Scale (SMAIS) is a self-reported questionnaire to assess the amount of assistance patients require to perform daily activities. Higher SMAIS scores indicate greater independence. (range: 0-44).

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
    Recruiting
    • Kang Zhang · Contact
    • Zaiqiang Zhang · Principal investigator
    • Yajie Wang · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2024 (actual). Primary completion is estimated for Dec 2027, 43 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 20, 2024
StartActual
May 10, 2024
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Dec 2026→Dec 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06421831
Lead sponsor
GeneCradle Inc
Responsible party
Sponsor
First posted
May 20, 2024
Start date
May 10, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

GeneCradle, Inc China
Contact
ind@bj-genecradle.com
+8613501380583

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion